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Interleukin 23–Helper T Cell 17 Axis as a Treatment Target
for Pityriasis Rubra Pilaris
Laurence Feldmeyer, MD, PhD; Alessio Mylonas, MSc; Olivier Demaria, PhD; AnnaMennella, MSc;
Nikhil Yawalkar, MD; Emmanuel Laffitte, MD; Daniel Hohl, MD; Michel Gilliet, MD; Curdin Conrad, MD
IMPORTANCE Treatment of pityriasis rubra pilaris (PRP) is solely based on its resemblance to
psoriasis rather than any knowledge of its pathomechanism. Insight into pathogenic
mediators of inflammation is essential for targeted and valid treatment options that could
replace previous serendipitous therapeutic approaches in refractory PRP.
OBJECTIVE To determine whether blockade of the interleukin 23–helper T cell 17 (IL-23–TH17)
pathway with ustekinumab represents an efficacious and, based on its proinflammatory
cytokine profile, targeted treatment option in PRP.
DESIGN, SETTING, AND PARTICIPANTS In this case report, a patient with PRP received
outpatient treatment at a university hospital department of dermatology with ustekinumab
according to the dosing regimen approved for psoriasis. Lesional skin biopsy samples were
taken from this patient and 2 others with refractory PRP. Messenger RNA (mRNA) expression
of proinflammatory innate and T-cell–derived cytokines were measured and compared with
skin samples from patients with psoriasis and healthy donors. From 1 patient, lesional skin
samples were taken before ustekinumab treatment and 4 and 28weeks after treatment
initiation. Follow-up was completed after 6months.
INTERVENTION Subcutaneous ustekinumab, 45mg, at weeks 0 and 4 and quarterly
thereafter.
MAIN OUTCOMES ANDMEASURES The primary outcomewas to determine the changes in
expression of proinflammatory innate and T-cell–derived cytokines during ustekinumab
therapy. The secondary objective was to evaluate the clinical and histopathologic phenotype
in relation to themRNA expression profile of proinflammatory cytokines.
RESULTS In lesional PRP skin samples from a single patient, upregulated expression levels
were found for most proinflammatory innate cytokines, including tumor necrosis factor
(TNF), IL-6, IL-12, IL-23, and IL-1β. Among adaptive T-cell cytokines, an increase of TH1
cytokines and, in particular, TH17 cytokines IL-17A, IL-17F, and IL-22 was seen in PRP. The
patient with PRPwho received ustekinumab showed regression of skin lesions after 2 weeks
and almost complete resolution after 1 month. Clinical and histopathologic improvement
paralleled the expression levels of TH17 cytokines but not of interferon-γ and TNF, which
lagged behind the amelioration.
CONCLUSIONS AND RELEVANCE In this case report, a role of the IL-23–TH17-axis in PRPwas
identified, suggesting a shared pathogenic inflammatory pathway with psoriasis, despite
evident clinical and histopathologic differences. In addition, this report provides a rationale
for targeting the IL-23–TH17-pathway as a treatment option for refractory PRP.
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P ityriasis rubra pilaris (PRP) is a chronic inflammatoryskin disease that typically appears sporadically and isacquired inmost cases.1 Pityriasis rubra pilaris is clini-
cally characterizedby follicularhyperkeratosisonanerythem-
atousbase.Thesepapulesshowatendencytocoalesce, thereby
forming large orange-red plaques with classic demarcated is-
landsof sparing. Pityriasis rubrapilaris frequently involves the
palms and soles, leading to palmoplantar orange-red waxy
keratoderma. Themajor clinical differential diagnosis is pso-
riasis. However, in its most common form, type 1 PRP is typi-
cally self-limited and resolves within 3 years in 80%of cases.
Basedon reported associationswithvarious autoimmunedis-
eases, such as myasthenia gravis, arthritis, and myositis, a
pathogenesisdrivenbyanaberrant immuneresponsehasbeen
suggested. However, the pathogenesis of PRP remains elu-
sive. Thus, treatment of PRP is mainly empirical and, owing
to its resemblance to psoriasis, classic treatments for psoria-
Figure 1. Expression of Helper T Cell 17 (TH17) and TH22 Cytokines in Skin Lesions of Pityriasis Rubra Pilaris (PRP)
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A, Clinical image of a patient in his 40s with PRP shows typical orange-red
follicular papules with scaly centers progressing to a widespread
suberythroderma with islands of normal skin. B, Histopathologic evaluation of
lesional skin with PRP shows a psoriasiform acanthosis (thickening of the
epidermis), irregular hyperkeratosis (thickening of the corneal layer) with
alternating vertical and horizontal orthokeratosis and parakeratosis
(characteristic checkerboard pattern), and keratin plugs in the follicles
(hematoxylin-eosin, bar indicates 100 μm). C, Relative messenger RNA (mRNA)
expression of innate cytokines and adaptive T-cell–derived cytokines in lesional
PRP skin compared with healthy skin shows particularly an upregulation of TH17
cytokines in PRP. Error bars represent range of duplicates. HS indicates healthy
skin; IFN-γ, interferon-γ; IL, interleukin; mRNA, messenger RNA; and TNF,
tumor necrosis factor.
Key Points
Question Does targeting the interleukin 23–helper T cell 17
pathway represent a targeted treatment option for pityriasis rubra
pilaris?
Findings In this case report, gene expression analyses of lesional
skin samples taken from 3 patients with pityriasis rubra pilaris
revealed a preferential helper T cell 17 expression profile. Analyses
of samples from 1 patient performed before and during
anti–interleukins 12 and 23 treatment with ustekinumab showed
that expression levels of helper T cell 17 cytokines, but not of
tumor necrosis factor or interferon-γ, paralleled clinical and
histologic improvements.
Meaning This report identifies a role of the interleukin 23–helper
T cell 17 axis in pityriasis rubra pilaris and provides a rationale for
targeting this pathway as a treatment option for refractory
pityriasis rubra pilaris.
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sis areused.Topical corticosteroids, vitaminDanalogues,pho-
totherapy, systemic retinoids,methotrexate disodium, cyclo-
sporine, and more recently anti–tumor necrosis factor (TNF)
agents have been described.1 In addition, isolated cases of ef-
fective treatment with combined anti–interleukins 12 and 23
(IL-12, IL-23) (ustekinumab) have been published.2,3 None of
these treatments was based on a pathophysiological ratio-
nale, but solely on the resemblance of PRP to psoriasis.
Hereinwereport that thecytokineexpression inPRPshows
a helper T cell 17 (TH17) and TH1 profile and that clinical im-
provement parallels the decrease in lesional TH17 cytokines
during effective anti–IL-12/IL-23 therapy. These findings sug-
gest a role for TH17 cytokines in PRP and provide basis for a
targeted treatment in blocking the IL-23–TH17 axis.
Methods
Skinbiopsy sampleswereobtained from3patientswithPRPat
specified time points. Skin sampleswere fixed using 4%para-
formaldehyde for histopathologic analysis or snap frozen and
storedat−80°C for reverse transcription–polymerase chain re-
actionanalysis (RT-PCR).Paraffin-embeddedskinsectionswere
deparaffinizedandstainedusingastandardhematoxylin-eosin
stainingprotocol.ForquantitativeRT-PCR,complementaryDNA
was synthesized using reverse transcriptase (SuperScript II;
Invitrogen), and relative geneexpressionwasquantifiedusing
specificprobes(TaqMan;LifeTechnologies)andcalculatedusing
the comparative CTmethod,where 2Δ-ΔCt describes the differ-
ence inCTvaluesbetween the target geneandnormalizer gene
[(CT geneof interest − CT internal control) sampleA − (CTgene
ofinterest − CTinternalcontrol)sampleB)]usingglyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as an endogenous con-
trol. Analyseswere performed in duplicates, andmeanvalues
ormean values plus the range of duplicates are depicted. This
studywas performed in accordancewith the guidelines of the
DeclarationofHelsinki4 andwasapprovedby thecantonal eth-
ics committeeofVaud,Switzerland.All patientsprovidedwrit-
ten informed consent.
Report of a Case
Aman inhis 40swith PRPpresentedwithpainful palmoplan-
tar hyperkeratosis, erythema of the face and scalp, and char-
acteristic confluent red to orange follicular papules progress-
ing to suberythroderma (Figure 1A). Diagnosiswas confirmed
by results of histopathologic analysis showing a psoriasiform
dermatitiswith irregular hyperkeratosis and the typical alter-
nating vertical and horizontal orthokeratosis and parakerato-
sis (checkerboard pattern), keratin plugs in the follicles, and a
sparse lymphohistiocytic, perivascular dermal infiltrate
(Figure 1B). Because PRP shares common features with pso-
riasis, we analyzedmessenger RNA (mRNA) expression of in-
nate and adaptive cytokines involved in psoriasis pathogen-
esis.We found upregulatedmRNA expression levels formost
proinflammatory innate cytokines, includingTNF, IL-6, IL-12,
IL-23, and IL-1β in the lesional skin sample of the patientwith
PRP comparedwith normal skin (Figure 1C). Among adaptive
T-cell cytokines, we found a particular increase of TH17 cyto-
kines IL-17A, IL-17F, and IL-22 inPRP comparedwith basal ex-
pression innormal skin, suggesting that these cytokinesmight
play a pathogenic role in PRP similar to that in psoriasis. Pref-
erential overexpression of TH17 cytokineswas confirmed in 2
additional patients with PRP, showing a similar profile
(Figure 2). Furthermore, cytokines of the IL-23–TH17 axis
showed comparable mRNA expression levels in all 3 patients
with PRP and in psoriasis.
Figure 2. Preferential Expression of Helper T Cell 17 and 22 (TH17 and TH22) Cytokines in Skin Lesions of Pityriasis Rubra Pilaris (PRP)
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Messenger RNA (mRNA) expression of innate cytokines and adaptive
T-cell–derived cytokines in the lesional skin samples of 3 patients (the patient in
Figure 1 and 2 additional patients) with PRP compared with healthy skin (HS)
confirms upregulation of proinflammatory innate cytokines and TH17 cytokines
in PRP. Triangles represent individual donor with HS; dots, individual patients
with PRP (open symbol corresponds to the patient in Figure 1). Horizontal bar
denotes themean value. IFN-γ indicates interferon-γ; IL, interleukin; and TNF,
tumor necrosis factor.
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In ourpatient, topical therapies remained insufficient; his
PRP was further aggravated despite 4 months of treatment.
Worsening of the dermatosis on sun exposure prevented us
fromusingphototherapy.Acitretinandmethotrexatewerecon-
traindicatedowing toahistoryofadrug-inducedhepatitiswith
ongoingelevationof liver enzyme levels.Because IL-23 is criti-
cal for the differentiation and expansion of TH17 cells,5,6 and
becausewe found a preferential overexpression of TH17 cyto-
kines, we opted for ustekinumab (Stelara), a human anti–
IL-12/IL-23 antibody approved for severe psoriasis.7
Subcutaneous ustekinumab, 45mg,was given atweeks 0
and4 andquarterly thereafter, according to the psoriasis dose
regimen. The lesions showed regression after 2 weeks and al-
most complete resolution after 1 month (Figure 3A). After 6
months,thetreatmentwasinterruptedandthepatientremained
in remission. The clinical improvement as reflected by the
4-pointPhysicianGlobalAssessment(ameasureofthemeanred-
ness, thickness,andscalingof the lesions,eachgradedonascale
of0-4,withhigher scores indicating increased severity) nicely
paralleled the mRNA expression of IL-17A and IL-17F and, to
somedegree,expressionof IL-22(Figure3B).Ontheotherhand,
although theexpressionofTNFand IFN-γdeclinedeventually,
theirdecreasemarkedlylaggedbehindtheclinical improvement,
whereas IL-1βandIL-10mRNAexpressionremainedunchanged
after6monthsoftreatment.Furthermore,theexpressionofTH17
cytokines also paralleled the improvement of histopathologic
findings, suchasnormalizationof theepidermal thickeningand
the corneal layer and attenuation of the cellular infiltrate
(Figure3C).This findingsuggestsa role forTH17cytokines in the
pathogenesis of PRP and in driving its skin phenotype.
Discussion
Studies of PRP treatment are hampered by the unclear patho-
genesis and the low incidence of the disease; therefore PRP
therapy is based on the results of small case series and case
reports.8,9 Consequently, the therapy for PRP remains largely
Figure 3. Change in Helper T Cell 17 (TH17) Cytokines in Pityriasis Rubra Pilaris (PRP) During TreatmentWith Ustekinumab
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A, Clinical image of the patient with PRP before (week 0) and week 4 after
initiation of anti–interleukins 12 and 23 (IL-12/IL-23) treatment (ustekinumab
[Stelara]) shows rapid improvement. B, Relative messenger RNA (mRNA)
expression of tumor necrosis factor (TNF), interferon-γ (IFN-γ), IL-10, IL-17A,
IL-17F, and IL-22 within the skin at weeks 0, 4, and 28. The different cytokines
are shown overlapped to the Physician Global Assessment (PGA) score to
analyze potential correlation of gene expressions with clinical improvement.
PGA scores range from0 to 4, with higher scores indicating greater severity.
Error bars represent range of duplicates. C, Histopathologic images of lesional
skin samples with PRP at weeks 0, 4, and 28 show reduction of acanthosis,
normalization of hyperkeratosis and parakeratosis toward orthokeratosis, and
disappearance of the dermal inflammatory infiltrate (hematoxylin-eosin).
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empirical and, owing to its clinical and histopathologic simi-
larities topsoriasis, classicpsoriasis treatments arebeingused.
In psoriasis, epidermal hyperplasia is driven by IL-23 and
mediated by IL-17 and IL-22, with IL-22 directly inducing ke-
ratinocyte hyperproliferation.10,11 Furthermore, the block-
ade of IL-12/IL-23, IL-23 specifically, and IL-17 have all been
proven effective in psoriasis.7,12,13 Epidermal thickening, hy-
perproliferationandaltereddifferentiationofkeratinocytesare
alsohallmarksofPRP, renderingTH17cells an interesting thera-
peutic target in PRP. Indeed, we found an increased TH17 ex-
pression profile in skin lesions of 3 patients with PRP and
showed that the expression levels of TH17 cytokines, but not
of TNFor the TH1 cytokine IFN-γ, paralleled clinical improve-
ment during anti–IL-12/IL-23 treatment. Pityriasis rubra pila-
ris is often self-limiting, but theprogressivedisease coursebe-
fore treatment and the rapid response after a single injection
strongly suggest that disease resolution was not spontane-
ous. Furthermore, previous reports in PRP described equally
rapid efficacy on initiation of ustekinumab treatment.3 Suc-
cessful anti–IL-17 treatment of a patient with refractory PRP
was also recently reported, which further supports an effi-
cacy of the IL-23–TH17 blockade in PRP.14
This study indicates a shared inflammatory pathway in
psoriasis and PRP. Interestingly, mutations in the caspase re-
cruitment domain family member 14 gene (CARD14 [HGNC
16446]) havebeen identified in bothdiseases, raising thepos-
sibility that CARD14 is upstream of the IL-23–TH17 pathway.
However, our patient did not display any CARD14 mutation
known in familial15 or sporadic16 PRP.Whether the efficacy of
blocking the IL-23–TH17 pathway is linked to a specific geno-
type and/or clinical subtype remains to be shown.
Despite pathogenic commonalities betweenpsoriasis and
PRP, obvious distinctions remain, such as orange-red waxy
keratoderma, follicular hyperkeratosis, and absence of neu-
trophils in PRP. Future studies should identify pathologic
mechanismsunderlying thesedifferences. Another feature of
PRP is its spontaneous resolution. Interestingly, we found
higher levels of IL-10 in PRP compared with psoriasis, which
persisted on treatment, suggesting a potential anti-
inflammatory pathway in PRP.
Limitations
This study has some limitations owing to the restricted num-
ber of patients included. Additional studies will need to fur-
ther corroborate our findings by treating larger cohorts of
patientswithPRPusingustekinumab,andanti–IL-17–andanti–
IL-23–specific antibodies.
Conclusions
This study identifies a role of the IL-23–TH17-axis in PRP,
suggesting a shared pathogenic inflammatory pathway with
psoriasis. The findings provide a rationale for targeting the
IL-23–TH17 axis as a treatment option for refractory PRP that
could replace previous serendipitous therapeutic approaches.
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